Cadila gets USFDA nod for Promethazine tablets

Cadila Healthcare has received US Food and Drug Administration (USFDA) approval to market Promethazine tablets, 12.5 mg, 25 mg and 50 mg.

According to a release issued by Cadila Healthcare to the BSE today, the company is planning to launch the drug soon. "The current sales of Promethazine tablets in the US market is estimated at $116 million," the release added.